Otsuka saw the highest growth of 101% in patent filings in January and 116% in grants in March in Q1 2024. Compared to Q4 2023, Q1 2024 saw an increase in patent filings by 101% and grants by 94%. GlobalData’s DataBook provides a comprehensive analysis of Otsuka‘s patent filings and grants. Buy the databook here.
Otsuka has been focused on protecting inventions in Japan(JP) with 44 publications in Q1 2024
The Japan(JP) Patent Office dominates the patent filings and grants with nearly 16% filings and 22% grants. The World Intellectual Property Organization(WIPO), Japan(JP), United States(US), and South Korea(KR) patent Office are among the top ten patent offices where Otsuka is filings its patents. Among the top granted patent authorities, Otsuka has 22% of its grants in Japan(JP), 19% in United States(US) and 10% in European Patent Office(EPO).
F. Hoffmann-La Roche and Pfizer could be the strongest competitors for Otsuka
Patents related to rare diseases and health & wellness lead Otsuka's portfolio
Otsuka has the highest number of patents in rare diseases followed by, health & wellness and addiction. For rare diseases, nearly 30% of patents were filed and 25% of patents were granted in Q1 2024.
Petrochemicals related patents lead Otsuka portfolio followed by automotive materials, and lung cancer
Otsuka has highest number of patents in petrochemicals followed by automotive materials, lung cancer, attention deficit hyperactivity disorder (adhd), and general surgery devices. For petrochemicals, nearly 4% of patents were filed and 4% of patents were granted in Q1 2024.
For comprehensive analysis of Otsuka's filings and grants, buy the databook here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.